Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Researchers have developed an endoscopic system, powered by artificial intelligence (AI), capable of identifying colorectal adenomas during a colonoscopy. Findings are set to be presented at the 25th UEG Week in Barcelona.
Tech giant Amazon has reportedly received approval to become a wholesale pharmacy distributor in at least a dozen states, according to the St. Louis Post-Dispatch.
In a place where the average highs are only in the 40s during the height of summer and where the sun isn’t visible from October through March, physicians have to be prepared for different kinds of incidents—like polar bear attacks.
The Agency for Healthcare Research and Quality has awarded the Regenstrief Institute with funding to study whether a health information exchange (HIE) improves patient outcomes in the emergency department (ED).
Scientist from the University of Surrey in the U.K. and China's Dalian University of Technology have developed smart nanoparticles capable of killing cancer cells and self-regulating heat to protect healthy tissue, according to a study published in Nanoscale.
Hospital pharmacists are scrambling for alternatives to drugs and medical supplies that are made in Puerto Rico, where production has halted due to the damage caused by Hurricane Maria.
Charleston Area Medical Center in Charleston, West Virginia, is struggling with a $40 million deficit, but has spent $12 million this year on “travel” nurses in order to keep the hospital operational.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.